Develops Deramiocel, a cell therapy for Duchenne muscular dystrophy, and exosome-based therapeutics and vaccines for rare diseases and other conditions.
10-K for FY2025, filed Mar 17, 2026Capricor Therapeutics, Inc. is a biotechnology company focused on the development and potential commercialization of cell and exosome-based…View ↗
Our core program is focused on the development and commercialization of Deramiocel, a cell therapy product candidate comprised of…View ↗
Our exosome platform is supported by internal research and external collaborations. Our collaborations and research around exosomes include…View ↗
10-Q for Q3 FY2026, filed Nov 10, 2026
−$42.7MView ↗
8-K, filed Aug 24, 2026
On August 24, 2026, Capricor Therapeutics, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug…View ↗
8-K, filed May 7, 2026
On May 7, 2026, Capricor announced that it has filed a Complaint for Equitable Relief and Application for Preliminary Injunction in the…View ↗
Deramiocel moves toward commercialization
The older report described the DMD cell therapy in a clinical study; the latest report says its application is under FDA review and the company is preparing for possible commercialization.
10-K for FY2022, filed Mar 17, 2023 10-K for FY2025, filed Mar 17, 2026We are currently enrolling the HOPE-3, Phase III clinical study investigating CAP-1002 for the treatment of late-stage DMD patients for the…View ↗
Exosome vaccine enters human testing
The older report described the engineered exosome vaccine as preclinical and said Capricor was seeking partners to move it into human testing; the latest report says a study run by the National Institutes of Health is underway.
10-K for FY2022, filed Mar 17, 2023 10-K for FY2025, filed Mar 17, 2026We are focused on developing a precision-engineered exosome platform technology that has the ability to deliver defined sets of effector…View ↗
We are developing an exosome-based vaccine candidate targeting SARS-CoV-2 using our exosome platform technology. This program is currently…View ↗
Competes with Sarepta Therapeutics and Nippon Shinyaku
10-K for FY2025, filed Mar 17, 2026Several exon-skipping therapies have been approved by the FDA for the treatment of certain subsets of patients with DMD who have specific…View ↗
Loading...